Suppr超能文献

载紫杉醇混合胶束的口服吸收改善及抗肺癌活性

Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles.

作者信息

Hou Jian, Sun E, Zhang Zhen-Hai, Wang Jing, Yang Lei, Cui Li, Ke Zhong-Cheng, Tan Xiao-Bin, Jia Xiao-Bin, Lv Huixia

机构信息

a Affiliated Hospital of Integrated Traditional Chinese and Western Medicine , Nanjing University of Chinese Medicine , Nanjing , Jiangsu , China.

b Key Laboratory of New Drug Delivery System of Chinese Meteria Medica, Jiangsu Province Academy of Traditional Chinese Medicine , Nanjing Jiangsu , China.

出版信息

Drug Deliv. 2017 Nov;24(1):261-269. doi: 10.1080/10717544.2016.1245370.

Abstract

The aim of this study was to establish a paclitaxel (PTX)-loaded mixed micelle delivery system (PTX-TP-M) with vitamin E-TPGS (TPGS) and Plasdone®S-630 Copovidone (PVPS630) as carriers to improve the solubility, oral absorption, and anti-tumor activity of PTX against lung cancer. In this study, PTX-TP-M was prepared using the ethanol thin-film dispersion method followed by characterization of the binary mixed micelles system. The average size of the PTX-TP-M was 83.5 ± 1.8 nm with a polydispersity index of 0.265 ± 0.007 and the drug loading (DL%) and entrapment efficiency (EE%) were 3.09 ± 0.09% and 95.67 ± 2.84%, respectively, which contributed to a high solubility of PTX about 24947-fold increase in water (4.78 ± 0.14 mg/mL). In addition, TEM analysis showed that the PTX-TP-M appeared spherical in structure and was well dispersed without aggregation and adhesion. In vitro release studies showed that the PTX-TP-M displayed a sustained release compared to free PTX in the dialysis bag. The efflux ratio of PTX reduced from 44.83 to 3.52 when formulated as PTX-TP-M; a 92.15% reduction, studied using the Caco-2 monolayer model. The oral bioavailability of PTX also improved by 4.35-fold, suggesting that PTX-TP-M can markedly promote the absorption in the gastrointestinal tract. Using in vitro MTT assays, it was observed that cytotoxicity was markedly increased, and IC values of PTX-TP-M (3.14 ± 0.85 and 8.28 ± 1.02 μg/mL) were lower than those of PTX solution (5.21 ± 0.93 and 14.53 ± 1.96 μg/mL) in A549 and Lewis cell, respectively. In vivo anti-tumor studies showed that PTX-TP-M achieved higher anti-tumor efficacy compared with PTX in Lewis bared C57BL/6 mice. Furthermore, a gastrointestinal safety assay also proved the safety of PTX-TP-M. All results demonstrated that the PTX-TP-M exhibited great potential for delivering PTX with increased solubility, oral bioavailability, and anti-cancer activity and this binary mixed micelles drug delivery system has potential to be used clinically.

摘要

本研究的目的是建立一种以维生素E-TPGS(TPGS)和聚维酮S-630共聚维酮(PVPS630)为载体的载紫杉醇(PTX)混合胶束递送系统(PTX-TP-M),以提高PTX的溶解度、口服吸收以及对肺癌的抗肿瘤活性。在本研究中,采用乙醇薄膜分散法制备PTX-TP-M,随后对二元混合胶束系统进行表征。PTX-TP-M的平均粒径为83.5±1.8nm,多分散指数为0.265±0.007,载药量(DL%)和包封率(EE%)分别为3.09±0.09%和95.67±2.84%,这使得PTX在水中的溶解度显著提高,约增加了24947倍(4.78±0.14mg/mL)。此外,透射电镜分析表明,PTX-TP-M呈球形结构,分散良好,无聚集和黏附现象。体外释放研究表明,与透析袋中的游离PTX相比,PTX-TP-M呈现出缓释特性。当制成PTX-TP-M时,PTX的外排率从44.83降至3.52;使用Caco-2单层模型研究发现降低了92.15%。PTX的口服生物利用度也提高了4.35倍,这表明PTX-TP-M可显著促进胃肠道吸收。通过体外MTT试验观察到,细胞毒性显著增加,在A549和Lewis细胞中,PTX-TP-M的半数抑制浓度(IC值)(分别为3.14±0.85和8.28±1.02μg/mL)低于PTX溶液(分别为5.21±0.93和14.53±1.96μg/mL)。体内抗肿瘤研究表明,在Lewis裸C57BL/6小鼠中,PTX-TP-M与PTX相比具有更高的抗肿瘤疗效。此外,胃肠道安全性试验也证明了PTX-TP-M的安全性。所有结果表明,PTX-TP-M在提高PTX的溶解度、口服生物利用度和抗癌活性方面具有巨大潜力,这种二元混合胶束药物递送系统具有临床应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f630/8241097/9995271725ce/IDRD_A_1245370_F0001_C.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验